Vicarius Pharma AG, a newly-launched company providing U.S.-based biopharmaceutical companies a novel approach to commercializing their first asset in European markets, has secured a CHF21 million (USD 21.8 million) investment through a Series A preferred stock financing from private investors. Vicarius acts as the innovator’s go-to-market organization for Europe, building a customer-facing organization and commercializing the asset in the innovator’s name, while absorbing all launch costs.
VISCHER acted as transaction counsel to Vicarius Pharma AG. The team includes Felix W. Egli (Partner, Corporate), team leader, and Stefan Kohler (Partner, Regulatory Life Science), Roland Müller (Partner, Notary), Christoph Niederer (Partner, Tax), Thomas Krizaj (Managing Associate, Corporate), Peter Kühn (Corporate) and Seraina Tsering (Banking & Finance).